bevacizumab
Pronunciation: be-vuh-SIZ-uh-mab
Other Name(s): Avastin®; Mvasi®; Zirabev®; Bambevi®; Abevmy®; Aybintio®; Vegzelma™
Apparence: Clear, colourless solution mixed into larger bags of fluids
Les renseignements du Formulaire de médicaments s’adressent aux professionnels de la santé. Il ne s’agit pas d’un avis médical. Certains des renseignements, y compris ceux sur le financement des médicaments anticancéreux, ne s’appliquent pas à tous les patients. Les plans de traitement du cancer sont propres à chaque patient. Si vous êtes un patient, veuillez parler avec votre équipe soignante pour comprendre comment ces renseignements s’appliquent à vous.
Drug Monograph
nov 2024
Eligibility Forms
Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Bevacizumab (Biosimilar) - Metastatic (Stage IVB) Persistent or Recurrent Carcinoma of the Cervix Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma Bevacizumab (Biosimilar) - Metastatic Colorectal Small Bowel or Appendiceal Cancer Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent GlioblastomaPatient Info Sheet
jul 2024
What it is used for
- For treating certain types of colorectal, lung, brain, ovarian, cervical, kidney and other cancers. It may be used alone or with other chemotherapy drugs, depending on the type of cancer.
- Bevacizumab is available as a biosimilar medication. See our biosimilar pamphlet for more information.